Barclays’s Filana Therapeutics FLNA Stock Holding History

Barclays’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-320,000	Closed	-$5.32M	–	5332
2023 Q3	$5.32M	Buy	+320,000	New	+$6.34M	﹤0.01%	1289

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Barclays's FLNA Position: Q2 2026 in Review

Barclays reduced its Filana Therapeutics (FLNA) stake by 99% in Q2 2026, selling an estimated $60K and leaving 292 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #5052.

Barclays first reported a position in FLNA in Q2 2013 and has held it in 27 quarters since. The position peaked at $4.85M in Q4 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Barclays held 292 shares of Filana Therapeutics worth $347 as of Q2 2026.
Barclays sold 42,087 Filana Therapeutics shares in Q2 2026, an estimated $60K.
Filana Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5052 holding.
Barclays first reported a position in Filana Therapeutics in Q2 2013 and has held it in 27 quarters since.
Barclays's Filana Therapeutics position peaked at $4.85M in Q4 2021.
84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.